Plasminogen activators in ischemic stroke: introduction.
作者信息
del Zoppo Gregory J
机构信息
Department of Medicine, University of Washington School of Medicine, Box 359756, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104, USA.
出版信息
Stroke. 2010 Oct;41(10 Suppl):S39-41. doi: 10.1161/STROKEAHA.110.595769.
Abstract
摘要
相似文献
1
Plasminogen activators in ischemic stroke: introduction.
Stroke. 2010 Oct;41(10 Suppl):S39-41. doi: 10.1161/STROKEAHA.110.595769.
2
Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).
Stroke. 2009 Sep;40(9):3156-8. doi: 10.1161/STROKEAHA.109.559682. Epub 2009 Jul 16.
3
Clinical inquiries. When should patients with stroke receive thrombolytics?
J Fam Pract. 2004 Aug;53(8):656, 658-9.
4
Treatment of acute ischemic stroke, Part 1.
J Am Pharm Assoc (Wash). 1996 Oct;NS36(10):571-2.
5
The concept of combination therapy in acute ischemic stroke.
Neurology. 1997 Nov;49(5 Suppl 4):S70-4. doi: 10.1212/wnl.49.5_suppl_4.s70.
6
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?
Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):164-5. doi: 10.1038/ncpcardio1447. Epub 2009 Jan 20.
7
Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
Int J Stroke. 2011 Feb;6(1):25-32. doi: 10.1111/j.1747-4949.2010.00537.x.
8
[Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
Rev Neurol (Paris). 2015 Dec;171(12):866-75. doi: 10.1016/j.neurol.2015.09.002. Epub 2015 Nov 10.
9
Overview: hyperacute rt-PA stroke treatment. The NINDS rt-PA Stroke Study Group.
J Neurosci Nurs. 1997 Dec;29(6):351-5. doi: 10.1097/01376517-199712000-00003.
10
Contemporary acute ischemic stroke therapy with intravenous recombinant tissue plasminogen activator.
Clin Neurosurg. 2000;46:261-6.
本文引用的文献
1
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.
Stroke. 2001 Jun;32(6):1341-8. doi: 10.1161/01.str.32.6.1341.
2
Laminin degradation by plasmin regulates long-term potentiation.
J Neurosci. 2000 Mar 1;20(5):2003-10. doi: 10.1523/JNEUROSCI.20-05-02003.2000.
3
Astrocyte regulation of endothelial tissue plasminogen activator in a blood-brain barrier model.
J Cereb Blood Flow Metab. 1998 Dec;18(12):1316-24. doi: 10.1097/00004647-199812000-00006.
4
Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase.
Int J Biochem Cell Biol. 1996 Oct;28(10):1141-50. doi: 10.1016/1357-2725(96)00055-6.
5
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.
J Biol Chem. 1996 Apr 26;271(17):10079-86. doi: 10.1074/jbc.271.17.10079.
6
Extracellular proteolysis in the adult murine brain.
J Clin Invest. 1993 Aug;92(2):679-85. doi: 10.1172/JCI116637.
7
Biological and clinical aspects of plasminogen activator inhibitor type 2.
Blood. 1995 Dec 1;86(11):4007-24.
8
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators.
J Cell Biol. 1982 Sep;94(3):631-6. doi: 10.1083/jcb.94.3.631.
9
Studies on the kinetics of plasminogen activation by tissue plasminogen activator.
Biochim Biophys Acta. 1982 Jun 24;704(3):461-9. doi: 10.1016/0167-4838(82)90068-1.
10
Effects of trypsin and plasmin treatment of myelin on the myelin-associated glycoprotein and basic protein.
J Neurochem. 1984 Aug;43(2):582-5. doi: 10.1111/j.1471-4159.1984.tb00938.x.
Zotero 插件